Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SHEN211 in Healthy Subjects
NCT06214858Phase 1Recruiting
- Sponsor
- JKT Biopharma Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHEN211 in coronavirus disease 2019 (COVID-19) (10 arms), sponsored by JKT Biopharma Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events. Started Dec 2023; status: recruiting.
02
Drugs
SHEN211
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06214858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06214858.